Recombinant ACE2 has also been proposed as a potential cure for SARS-CoV-2’s most severe symptoms [78], and in vitro studies have shown that soluble forms of ACE2 are beneficial to SARS patients, likely because they act as competitive binders of SARS-CoV Spike proteins, preventing binding to the host cell ACE2 [79]. This evidence concerns the gene ACE2 and severe acute respiratory syndrome.